Literature DB >> 22673838

Management of uveal melanomas: cycloxygenase-2 as a potential molecular target.

Shailendra Kapoor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22673838     DOI： 10.1007/s10792-012-9594-5

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN： 0165-5701            Impact factor:   2.031


× No keyword cloud information.
  6 in total

1.  The expression of cyclooxygenase 2 in retinoblastoma: primary enucleated eyes and enucleation after conservative treatment.

Authors:  João Pessoa Souza Filho; Maria C Martins; Zelia Maria S Correa; Alexandre N Odashiro; Emilia Antecka; Anamaria B Coutinho; Carla R Macedo; Raul N G Vianna; Miguel N Burnier
Journal:  Am J Ophthalmol       Date:  2006-10       Impact factor: 5.258

2.  The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma.

Authors:  Jean-Claude A Marshall; Bruno F Fernandes; Sebastian Di Cesare; Shawn C Maloney; Patrick T Logan; Emilia Antecka; Miguel N Burnier
Journal:  Carcinogenesis       Date:  2007-04-13       Impact factor: 4.944

3.  Clinical activity of celecoxib in metastatic malignant melanoma.

Authors:  Kenneth S Wilson
Journal:  Cancer Invest       Date:  2006-12       Impact factor: 2.176

4.  Expression of COX-2 and prognostic outcome in uveal melanoma.

Authors:  Lorna M Cryan; Luminita Paraoan; Paul Hiscott; Bertil E Damato; Ian Grierson; Donna Gray; Michael Farrell; Glen A Doherty; Desmond J Fitzgerald; Colm O'Brien
Journal:  Curr Eye Res       Date:  2008-02       Impact factor: 2.424

5.  Amfenac increases the radiosensitivity of uveal melanoma cell lines.

Authors:  B F Fernandes; J-C Marshall; S Di Cesare; P Logan; S Maloney; M N Burnier
Journal:  Eye (Lond)       Date:  2007-11-30       Impact factor: 3.775

6.  Cyclooxygenase-2 expression in human irradiated uveal melanomas.

Authors:  Pinar C Ozdal; Sonia Callejo; Amanda L Caissie; Chaim Edelstein; Silvin Bakalian; Raul N G Vianna; Miguel N Burnier
Journal:  Int Ophthalmol       Date:  2007-06-30       Impact factor: 2.031
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.